AquIRE reveals the mechanisms of clinically induced RNA damage and the conservation and dynamics of glycoRNAs

Zijian Zhang, Zornitsa Vasileva Kotopanova, Kexin Dang, Xiangxu Kong, Nicole Simms, Tin Wai Yuen, Lan Lam, Lauren Forbes Beadle, Emma Hilton, Taqdees Qureshi, Marianna Coppola, Chris Holmes, Kwan Ting Kan, Mark Ashe, Patrick Gallois, Hilary Ashe, Michael Braun, Mark Saunders, P. Sutton, David J. Thornton, John R. P. KnightNucleic 2026 · DOI

TL;DR

This paper introduces AquIRE, a novel, sensitive, and flexible platform for quantifying RNA modifications, including drug-induced damage and glycan conjugation. Using AquIRE, the researchers reveal previously unappreciated temporal dynamics of RNA damage by common chemotherapies and demonstrate the widespread presence and dynamic nature of glycoRNAs across diverse organisms, even in cell-free environments.

What Problem Does This Paper Address?

For decades, the focus of chemotherapy's impact has been primarily on DNA damage. However, recent research highlights RNA as a significant target for many clinical compounds, influencing their efficacy and side effects. Understanding how drugs damage RNA and how cells respond is crucial for developing more effective and targeted therapies. Furthermore, while RNA modifications like methylation (the "epitranscriptome") and glycan conjugation (glycoRNAs) are increasingly recognized for their roles in cellular processes, studying them has been hampered by a lack of sensitive and versatile detection methods. Existing techniques often require specialized reagents, complex imaging, or are not amenable to high-throughput analysis. This paper aims to bridge this gap by developing a robust method to quantify diverse RNA modifications, enabling deeper insights into drug-RNA interactions and the biology of glycoRNAs.

Methods

The core innovation presented is the Aqueous Identification of RNA Elements (AquIRE) platform. This method overcomes limitations of traditional RNA analysis, particularly those involving immobilization on membranes which can obscure epitopes. AquIRE works by:

  1. Polyadenylation: Adding a poly(A) tail to purified RNA to provide a consistent anchor point.
  2. Immobilization: Tying the RNA to magnetic oligodT beads via the poly(A) tail, leaving the RNA surface accessible.
  3. Detection: Incubating the immobilized RNA with specific primary antibodies (for drug adducts or endogenous modifications) or glycan-binding lectins.
  4. Secondary Detection: Using biotinylated secondary antibodies and fluorescently labeled streptavidin for signal amplification.
  5. Elution and Reading: Eluting the bound complexes with nuclease-free water and measuring fluorescence.

This approach is highly sensitive, requiring as little as 10 ng of RNA, and is intrinsically flexible, allowing for the detection of various RNA elements by simply changing the primary detection molecule. The authors also employed standard techniques like RNA isolation (using Zymo Quick-RNATM Miniprep Kit), qPCR for cDNA stalling assays, and LC-MS for confirmation of specific modifications.

Datasets

The study utilized various biological samples for analysis, including:

  • Cell Lines: Human colorectal cancer cell lines (HCT116, LS174T, DLD1, RKO, JVE-127, JVE-253) and glioblastoma cell lines (A172, U251).
  • Animal Tissues: Adult wild-type mice (Mus musculus) tissues (spleen, colon, lung, liver, kidney, heart, brain, blood).
  • Model Organisms: Arabidopsis thaliana (plants), Drosophila melanogaster (fruit flies), Saccharomyces cerevisiae (yeast), and Escherichia coli (bacteria).
  • Clinical Samples: Colorectal primary or metastatic tumours from human patients.
  • Biofluids: Mouse plasma, commercial goat serum, and fetal bovine serum.
  • In vitro transcribed (IVT) RNA: Used as controls and for method validation.

No new benchmarks were introduced; rather, the study focused on applying the novel AquIRE method to existing biological questions and sample types.

Key Insights and Ideas

  • RNA is a Major Target of Chemotherapy: The study strongly reinforces that common chemotherapies like 5FU, oxaliplatin, and temozolomide directly damage RNA, not just DNA. This damage has distinct temporal dynamics for each drug.
  • Temporal Dynamics of RNA Damage: Different drugs induce RNA damage at vastly different rates. 5FU and temozolomide cause rapid damage (<30 min), while oxaliplatin requires several hours (>6 h) at clinically relevant doses. This suggests distinct activation and metabolism pathways.
  • GlycoRNAs are Ubiquitous and Dynamic: GlycoRNAs, RNA molecules conjugated with glycans, are not confined to mammals. They are found across diverse life forms, including plants, insects, yeast, and bacteria, and even in cell-free environments like media and plasma. Their expression is dynamic, changing with embryonic development and senescence.
  • Cell-Free GlycoRNAs Play a Functional Role: The research suggests that cell-free or cell-surface glycoRNAs are not just bystanders but actively contribute to the efficacy of certain chemotherapies, specifically promoting the cytotoxicity of 5FU.
  • AquIRE as a Versatile Tool: The AquIRE platform proves to be a powerful, sensitive, and flexible tool for studying a wide range of RNA modifications, from drug adducts to endogenous epitranscriptomic marks and glyco-modifications, using minimal RNA input.

Key Results

  • Drug-Induced RNA Damage: AquIRE successfully detected and quantified 5FU, oxaliplatin, and temozolomide adducts on RNA.
  • 5FU incorporation into RNA was rapid and dynamic, showing a biphasic pattern with peaks at 30 minutes and 24 hours.
  • Oxaliplatin caused detectable RNA damage after 6 hours at high doses and 24 hours at lower, clinically relevant doses. Cisplatin and carboplatin did not show significant RNA damage.
  • Temozolomide induced reversible changes in RNA methylation (m7G, m6A, m5C) with distinct temporal profiles.
  • Epitranscriptome Analysis: AquIRE sensitively detected endogenous RNA modifications like m6A and pseudouridine (Ψ) across different cell lines, tissues, and even in Drosophila embryos.
  • GlycoRNA Detection and Distribution:
    • GlycoRNAs were detected in all tested colorectal cancer cell lines, with mucinous subtypes showing higher extracellular glycoRNA levels.
  • GlycoRNAs were found in cell-free media, blood plasma, and even in human tumour samples, suggesting their release into the extracellular environment.
  • Across species, glycoRNAs were detected in Arabidopsis, Drosophila, S. cerevisiae, and E. coli.
  • In Arabidopsis, glycoRNA levels decreased significantly during senescence.
  • In Drosophila embryos, glycoRNAs were maternally deposited and increased during development.
  • Functional Role of GlycoRNAs: In HCT116 cells, treatment with RNase A (which degrades cell-free RNA) significantly reduced 5FU cytotoxicity, indicating that cell-free glycoRNAs are required for optimal 5FU efficacy.

Limitations and Future Work

  • Lectins and Specificity: While AquIRE is flexible, the specificity of lectin binding can be a limitation. Some lectins may have high background binding to IVT RNA, and further investigation into lectin specificity and potential cross-reactivity is warranted. The paper notes that lectins can bind alternative glycans with lower affinity.
  • Quantitative vs. Relative Measures: The AquIRE method primarily provides relative quantification of RNA modifications. While it can detect differences in glycoRNA quantity, it doesn't provide absolute counts of glycans per RNA molecule. Future single-molecule methods are suggested to address this.
  • Mechanism of GlycoRNA Release: The study observed higher glycoRNA levels in cell-free fractions than total RNA, suggesting an active mechanism for glycoRNA delivery into the extracellular environment, which remains to be elucidated.
  • Clinical Correlation: While glycoRNAs were detected in human tumours, further studies are needed to investigate how glycoRNA expression correlates with patient responses and disease progression.
  • Expanding Glycan Detection: The authors suggest that expanding the repertoire of glycan detection using further lectins is an obvious approach for future work.
  • RNA Glycosylation vs. Protein Glycosylation: The study highlights that RNA glycosylation pathways may differ from canonical protein glycosylation, emphasizing the need for dedicated research in this area.

The AquIRE platform's flexibility and scalability offer exciting prospects for future discovery science in RNA biology, particularly in understanding the roles of RNA modifications in disease and drug response.

Summary updated

Abstract

RNA is subject to many modifications, from small chemical changes like methylation to conjugation of biomolecules such as glycans. As well as endogenously written modifications, RNA is also exposed to damage induced by its environment. Certain clinical compounds are known to covalently modify RNA with a growing appreciation of how these impact clinical efficacy. To understand the regulation of these modifications, we need a reliable, sensitive, and rapid methodology for their quantification. Thus, we developed Aqueous Identification of RNA Elements (AquIRE) and applied it to the analysis of drug-induced RNA damage by 5FU, oxaliplatin, and temozolomide in clinically relevant cell models. We demonstrate that RNA damage is widespread and follows previously unappreciated temporal dynamics. AquIRE also provides a highly sensitive method to detect RNAs modified by glycans. We leverage this to expand the horizons of the glycoRNA world across the kingdoms of life as well as identifying cell-free glycoRNAs in multiple species. We demonstrate that glycoRNA expression is dynamic during embryo development, modulated during senescence, and elevated by RNA-damaging agents. Finally, we use RNA digestion to demonstrate that cell surface or cell-free RNA promotes the cytotoxicity of RNA-damaging chemotherapy. Together, the AquIRE platform provides an intrinsically flexible method to study diverse RNA modifications from any sample.
BibTeX
@inproceedings{zhang2026aquire,
  author = {Zijian Zhang and Zornitsa Vasileva Kotopanova and Kexin Dang and Xiangxu Kong and Nicole Simms and Tin Wai Yuen and Lan Lam and Lauren Forbes Beadle and Emma Hilton and Taqdees Qureshi and Marianna Coppola and Chris Holmes and Kwan Ting Kan and Mark Ashe and Patrick Gallois and Hilary Ashe and Michael Braun and Mark Saunders and P. Sutton and David J. Thornton and John R. P. Knight},
  title = {{AquIRE reveals the mechanisms of clinically induced RNA damage and the conservation and dynamics of glycoRNAs}},
  booktitle = {Nucleic},
  year = {2026},
  doi = {10.1093/nar/gkag080},
}
Figure